Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein

被引：0
|
作者：
van Winkel, Claudia A.
Fan, Xiaoyu
Giesen, Danique
Gauderat, Glenn
Pattarini, Lucia
Jaquin, Thomas
Barakat, Anissa
De La Bigne, Anne-Marie
Richter, Marleen
Andersen, Nicole
Legrand, Julie
Lelievre, Helene
de Vries, Elisabeth G.
Morales-Kastresana, Aizea
Lub-de Hooge, Marjolijn N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3579
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3579
引用
收藏
页数：3
相关论文
共 50 条
  • [21] BH3120, a bispecific antibody targeting 4-1BB and PD-L1 simultaneously, stimulates T cells in tumor tissue preferred manner
    Wang, Jing
    Wang, Jun
    Liu, Yang
    Pang, Yan
    Zhang, Aihong
    Feng, Jie
    Sun, Aibo
    Ma, Xiao
    Cai, Jingmei
    Xu, Jiangcheng
    Liu, Jiawang
    Lee, Kyoungwoo
    CANCER RESEARCH, 2023, 83 (07)
  • [22] 89Zr标记PD-1/PD-L1单抗免疫PET显像应用研究进展
    郑晨
    李翠
    影像研究与医学应用, 2021, 5 (12) : 3 - 4
  • [23] Immuno-PET imaging using 89Zr labeled PD-L1 antibody in non-small cell lung cancer Xenograft
    Li, Dan
    Zhu, Xiao-Hua
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [24] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
    Xue, Junli
    Sun, Yuping
    Li, DaPeng
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats
    Bouleau, Alizee
    Nozach, Herve
    Dubois, Steven
    Kereselidze, Dimitri
    Chevaleyre, Celine
    Wang, Cheng-, I
    Evans, Michael J.
    Lebon, Vincent
    Maillere, Bernard
    Truillet, Charles
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (08) : 1259 - 1265
  • [26] An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
    Lian-sheng Cheng
    Min Zhu
    Yan Gao
    Wen-ting Liu
    Wu Yin
    Pengfei Zhou
    Zhongliang Zhu
    Liwen Niu
    Xiaoli Zeng
    Dayan Zhang
    Qing Fang
    Fengrong Wang
    Qun Zhao
    Yan Zhang
    Guodong Shen
    Cellular & Molecular Biology Letters, 28
  • [27] An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
    Cheng, Lian-sheng
    Zhu, Min
    Gao, Yan
    Liu, Wen-ting
    Yin, Wu
    Zhou, Pengfei
    Zhu, Zhongliang
    Niu, Liwen
    Zeng, Xiaoli
    Zhang, Dayan
    Fang, Qing
    Wang, Fengrong
    Zhao, Qun
    Zhang, Yan
    Shen, Guodong
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2023, 28 (01)
  • [28] A COMPUTATIONAL SEMI-MECHANISTIC PHARMACOLOGY MODEL OF ATG101, A PD-L1/4-1BB BISPECIFIC ANTIBODY FOR TREATMENT OF SOLID TUMORS AND NHL
    Flowers, David
    Presler, Marc
    Subramanian, Kas
    Yuraszeck, Theresa
    Hui Yuwen
    Hou, Bing
    Hoenemann, Dirk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A241 - A242
  • [29] BH3120, PD-L1 X 4-1BB bispecific antibody, plus PD-1 antagonist results in synergistic anti-tumor efficacy with excellent safety profile
    Wang, Jun
    Wang, Jing
    Liu, Yang
    Xu, Jiangcheng
    Liu, Jiawang
    Lee, Kyoungwoo
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors.
    Jungels, Christiane
    Kotecki, Nuria
    Calvo, Emiliano
    Garralda, Elena
    Price, Timothy
    Zahn, Xiaojiang
    Abbas, Atif
    Mahnke, Lisa
    Rauschning, Winrich
    Morales-Kastresana, Aizea
    Pattarini, Lucia
    Bossenmaier, Birgit
    Scholer-Dahirel, Alix
    Demuth, Tim
    Legrande, Julie
    CANCER RESEARCH, 2022, 82 (12)
12345